Paroxetine hydrochloride - Depression
You are here : Home > Formulary Search > Paroxetine hydrochloride - Depression
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
Green
Formulations :
- Tablets
Formulary Status :
Associated Icons :
Restrictions / Comments :
Documentation
PAD Profile
ChemicalSubstance :
Paroxetine hydrochloride
Indication :
Depression
Group Name :
Keywords :
SSRIs, selective serotonin re-uptake inhibitors, antidepressants
Brand Names Include :
Seroxat
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1
Other Indications
Below are listed other indications that Paroxetine hydrochloride is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Depression.
- Amitriptyline hydrochloride
- Bupropion hydrochloride
- Citalopram
- Clomipramine hydrochloride
- Duloxetine hydrochloride
- Esketamine hydrochloride
- Fluoxetine hydrochloride
- Fluvoxamine maleate
- Imipramine hydrochloride
- Isocarboxazid
- Lithium - adults
- Lofepramine hydrochloride
- Mianserin hydrochloride
- Mirtazapine
- Moclobemide
- Nortriptyline
- Phenelzine sulfate
- Quetiapine
- Reboxetine
- Sertraline
- Tranylcypromine sulfate
- Trimipramine maleate
- Venlafaxine
- Vortioxetine
Committee Recommendations (1)
Paroxetine has been considered by the PCN and has been assigned a GREEN traffic light status, within its LICENSED indication(s).
NOTE - the branded product (Seroxat) was considered BLACK at the PCN in May 2017.
Note - The Mood Hive and associated local depression and anxiety treatment guidelines have been removed from PAD.
Updated guidelines and resources for treating and managing depression in adults are being developed by Surrey & Borders Partnership. For current advice, in line with NICE guidance, please see the Clinical Knowledge Summaries - link provided below
NOTE - the branded product (Seroxat) was considered BLACK at the PCN in May 2017.
Note - The Mood Hive and associated local depression and anxiety treatment guidelines have been removed from PAD.
Updated guidelines and resources for treating and managing depression in adults are being developed by Surrey & Borders Partnership. For current advice, in line with NICE guidance, please see the Clinical Knowledge Summaries - link provided below